← All articles

MOTS-C Research: Human Evidence and Safety Gaps

Bookmark this page

Save this article in your browser so you can find it again:

  • Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
  • iPhone or iPad: In Safari, tap Share, then Add Bookmark.
  • Android: In Chrome, open the menu and tap the star.

Other browsers may use a different menu.

MOTS-C is a mitochondrial-derived peptide studied in cellular metabolism and exercise biology. Human studies that measure the body's own MOTS-C answer a different question from experiments that administer a compound. This guide compares selected foundational studies with newer human biomarker reports and explains why their findings do not establish a human performance, weight-loss or longevity benefit from a research vial.

At a glance:

  • Cell experiments investigate mechanisms, not patient outcomes.

  • The human exercise study measured naturally occurring MOTS-C; treatment experiments were in mice.

  • Study findings do not establish the safety or performance of a catalog product.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. Source-access limits appear below.

MOTS-C evidence map: cell experiments, mouse experiments with externally supplied material, and human exercise measurements of naturally occurring MOTS-C.
The human exercise component measured endogenous MOTS-C. It should not be merged with the separate mouse experiments into a claim of demonstrated human treatment benefit.

1. What is MOTS-C?

The original 2015 report described MOTS-c as a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA region. The authors investigated cellular metabolism and mouse models, reporting effects involving the folate pathway and AMPK, a cellular energy-sensing regulator. These findings established a research direction; they did not establish a human treatment or validate a commercial vial. Lee and colleagues, 2015

When reading a paper, distinguish endogenous MOTS-C, measured within an organism, from externally supplied material used in an experiment. Also record whether a study uses the named peptide, a modified research probe, or an analog. A related name alone is not evidence that two materials are interchangeable.

2. What did the cell experiments investigate?

A 2018 study examined movement of MOTS-c into the cell nucleus during metabolic stress. The authors reported AMPK-dependent nuclear localization and changes in stress-responsive gene regulation. This was a mechanistic investigation of communication between mitochondria and the nucleus, not a demonstration that a person taking MOTS-C would experience a particular health outcome. Kim and colleagues, 2018

For a reader, the useful question is specific: what did the assay measure? A change in location or gene expression is a different endpoint from a change in symptoms, daily function, or long-term safety. Neither endpoint should be silently substituted for the other.

3. Did the exercise study give MOTS-C to people?

The 2021 report included exercise measurements in ten healthy young male volunteers. Researchers measured naturally occurring MOTS-c in muscle and blood around a cycling session. They did not test administering MOTS-C to those participants. The small, narrowly defined group also limits generalization. Reynolds and colleagues, 2021

The same paper included separate mouse experiments with externally supplied MOTS-c. It reported improvements in some physical-performance measures, but not every outcome: the young-mouse experiments did not show improved grip strength or performance in a maze-based learning and memory test. Combining the human observations and mouse experiments into a claim of demonstrated human performance enhancement would misrepresent the design. Original results, including Supplementary Figure 2 references

What do newer human studies add?

A 2025 study compared serum MOTS-c and exercise-capacity measurements in marathon runners and sedentary people, alongside separate mouse experiments. Its human component examined an association; it was not a trial of giving MOTS-C to people. Feng and colleagues — abstract

A report published online in December 2025, in a 2026 issue, compared 32 adults with obesity with 22 lean controls. Circulating MOTS-c was higher in the obesity group. In ten participants assessed again six months after bariatric surgery, it did not change significantly despite weight reduction. The authors call this an exploratory study requiring independent validation. Yoon and colleagues — abstract

Research evidence map

Human evidence

What was examined

What it cannot establish

2021 cycling study

Endogenous MOTS-c around exercise in ten young men

Effects of administering MOTS-C

2025 endurance study

Serum MOTS-c and exercise-capacity associations

That changing the peptide causes better performance

2025/2026 obesity study

Circulating levels before and after weight reduction in a small subgroup

That a higher or lower concentration is always beneficial

These comparisons make a simple “more MOTS-C is better” story unreliable. A biomarker can change with a biological state without being its cause or a validated treatment target. The table summarizes the 2021 human measurements, endurance abstract and obesity abstract.

Is CB4211 the same evidence as native MOTS-C?

No. CohBar's own filing describes CB4211 as an analogue of MOTS-c. ClinicalTrials.gov lists its phase 1 study, NCT03998514, as completed, with 88 participants and CB4211 as the intervention. On November 11, 2026, that registry record had no posted results. An analogue programme and a registry entry do not establish efficacy or safety for native MOTS-C or a catalog vial. Sponsor's identity statement, trial record

4. How should readers judge the evidence?

Use four questions when comparing a headline with its source:

  • Material: Was the exact compound identified, including any modification?

  • Model: Were the results from cells, animals, or people?

  • Comparison: Was there an appropriate control, and what was measured?

  • Limits: Were unchanged outcomes, uncertainty, and conflicts disclosed?

The three foundational papers from 2015, 2018 and 2021 address different experimental questions and share Changhan Lee as an investigator. They should not be presented as three independent replications of one result. The 2018 and 2021 records also disclose commercial interests involving CohBar. Neither shared authorship nor disclosed interests alone invalidate a finding; this selection does not establish whether independent replication exists elsewhere. 2015 authors, 2018 disclosure, 2021 disclosure

5. What safety and material limits remain?

What is known about MOTS-C side effects?

The selected human biomarker studies do not supply a side-effect rate for administered MOTS-C. FDA's current compounding-risk entry identifies potential immune-response risks, peptide impurities and chemical-characterization difficulties, and says important human-safety information is missing. That entry is under nominations that were withdrawn. It is not a test of our inventory. FDA safety context, checked November 11, 2026

FDA's July 2026 presentation reported that its assessment had not identified clinical administration evidence for MOTS-c-related bulk substances. That is a dated assessment, not a claim that no later report could exist. The October 30 HHS notice subsequently announced a nonbinding draft enforcement-discretion policy for certain peptide compounding; such a policy is not drug approval or a clinical efficacy result. FDA presentation, MOTS-c clinical sections, HHS notice

This review makes no conclusion about the identity, purity, amount, safety, or performance of any current inventory lot. A published experiment is not a certificate of analysis for a supplier's material. Nor does detecting a peptide naturally in people establish the safety of administering an externally supplied product.

Keep the literature record and material record separate. Save the study citation with its model and endpoint; separately request documents identifying the material and its lot. This summary is not a dosing guide or a substitute for qualified scientific review.

Review method and source access

The foundational source checks were completed September 27, 2026. This November 11 update checked the indexed Feng and Yoon abstracts, selected indexed sections of the Reynolds report, the CB4211 registry record and sponsor identity statement, and the cited FDA/HHS materials. Some publisher and PMC pages could not be opened directly; indexed primary-source text was used where identified. These selected sources do not constitute a systematic literature search, independent scientific review, participant-data reanalysis or current-lot testing.

For a different clinical-evidence pathway, compare the SS-31 and elamipretide guide.

For the documentation side, see our guide to COAs, HPLC, and mass spectrometry and research peptide documentation checklist. More reading is available in the research resource library.

Bio Peptides Labs catalog materials are offered for lawful laboratory research only, not for human or veterinary use. The cited findings are not claims that our products reproduce the reported results.